GW Hunninghake and AR Kalica
Division of Pulmonary, Critical Care, and Occupational Medicine, University of Iowa, College of Medicine.

There was a general consensus at the workshop that pulmonary fibrosis is a highly lethal lung disorder and that current therapies for this disease have little effect on the natural history of the disease. There was also broad consensus that much has been learned about the pathogenesis of this disease in recent years and this information can be used to direct new therapies for this disease. As a complement to the findings from studies on pulmonary fibrosis itself, there has also been significant development of new therapies for other disorders that might be useful in treating patients with pulmonary fibrosis. The following is a list of some of the issues and recommendations that were generated from this workshop.

This article has been cited by other articles:

				S. Shi, J. Wu, H. Chen, H. Chen, J. Wu, and F. Zeng Single- and Multiple-Dose Pharmacokinetics of Pirfenidone, an Antifibrotic Agent, in Healthy Chinese Volunteers J. Clin. Pharmacol., October 1, 2007; 47(10): 1268 - 1276. [Abstract] [Full Text] [PDF]

				H. A. Jones Inflammation Imaging Proceedings of the ATS, December 1, 2005; 2(6): 545 - 548. [Abstract] [Full Text] [PDF]

				T. Kakugawa, H. Mukae, T. Hayashi, H. Ishii, K. Abe, T. Fujii, H. Oku, M. Miyazaki, J. Kadota, and S. Kohno Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis Eur. Respir. J., July 1, 2004; 24(1): 57 - 65. [Abstract] [Full Text] [PDF]

				B. Tian, L. Han, J. Kleidon, and C. Henke An HSV-TK Transgenic Mouse Model to Evaluate Elimination of Fibroblasts for Fibrosis Therapy Am. J. Pathol., August 1, 2003; 163(2): 789 - 801. [Abstract] [Full Text] [PDF]

				Y.-W. Tang, J. E. Johnson, P. J. Browning, R. A. Cruz-Gervis, A. Davis, B. S. Graham, K. L. Brigham, J. A. Oates Jr., J. E. Loyd, and A. A. Stecenko Herpesvirus DNA Is Consistently Detected in Lungs of Patients with Idiopathic Pulmonary Fibrosis J. Clin. Microbiol., June 1, 2003; 41(6): 2633 - 2640. [Abstract] [Full Text] [PDF]

				Y. Li, A. Azuma, S. Takahashi, J. Usuki, K. Matsuda, A. Aoyama, and S. Kudoh Fourteen-Membered Ring Macrolides Inhibit Vascular Cell Adhesion Molecule 1 Messenger RNA Induction and Leukocyte Migration: Role in Preventing Lung Injury and Fibrosis in Bleomycin-Challenged Mice Chest, December 1, 2002; 122(6): 2137 - 2145. [Abstract] [Full Text] [PDF]

				K.M. Beeh, J. Beier, I.C. Haas, O. Kornmann, P. Micke, and R. Buhl Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis Eur. Respir. J., June 1, 2002; 19(6): 1119 - 1123. [Abstract] [Full Text] [PDF]

				J V Barbas-Filho, M A Ferreira, A Sesso, R A Kairalla, C R R Carvalho, and V L Capelozzi Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP) J. Clin. Pathol., February 1, 2001; 54(2): 132 - 138. [Abstract] [Full Text] [PDF]

				G. Gurujeyalakshmi, Y. Wang, and S. N. Giri Taurine and Niacin Block Lung Injury and Fibrosis by Down-Regulating Bleomycin-Induced Activation of Transcription Nuclear Factor-kappa B in Mice J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 82 - 90. [Abstract] [Full Text]

				W. W. DOUGLAS, J. H. RYU, and D. R. SCHROEDER Idiopathic Pulmonary Fibrosis . Impact of Oxygen and Colchicine, Prednisone, or No Therapy on Survival Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1172 - 1178. [Abstract] [Full Text]

				K. TAMAGAWA, Y. TAOOKA, A. MAEDA, K. HIYAMA, S. ISHIOKA, and M. YAMAKIDO Inhibitory Effects of a Lecithinized Superoxide Dismutase on Bleomycin-Induced Pulmonary Fibrosis in Mice Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1279 - 1284. [Abstract] [Full Text]

				T. King Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment . International Consensus Statement Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 646 - 664. [Full Text]

				R. J. MASON, M. I. SCHWARZ, G. W. HUNNINGHAKE, and R. A. MUSSON Pharmacological Therapy for Idiopathic Pulmonary Fibrosis . Past, Present, and Future Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1771 - 1777. [Full Text]

				S. N. Iyer, G. Gurujeyalakshmi, and S. N. Giri Effects of Pirfenidone on Procollagen Gene Expression at the Transcriptional Level in Bleomycin Hamster Model of Lung Fibrosis J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 211 - 218. [Abstract] [Full Text]

				G. RAGHU, W. CRAIG JOHNSON, D. LOCKHART, and Y. MAGETO Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone . Results of a Prospective, Open-label Phase II Study Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): 1061 - 1069. [Abstract] [Full Text] [PDF]

				D. W Mapel, W. C Hunt, R. Utton, K. B Baumgartner, J. M Samet, and D. B Coultas Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts Thorax, June 1, 1998; 53(6): 469 - 476. [Abstract] [Full Text]

				A.-L. A. KATZENSTEIN and J. L. MYERS Idiopathic Pulmonary Fibrosis . Clinical Relevance of Pathologic Classification Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1301 - 1315. [Full Text] [PDF]

				Y. TAOOKA, A. MAEDA, K. HIYAMA, S. ISHIOKA, and M. YAMAKIDO Effects of Neutrophil Elastase Inhibitor on Bleomycin-Induced Pulmonary Fibrosis in Mice Am. J. Respir. Crit. Care Med., July 1, 1997; 156(1): 260 - 265. [Abstract] [Full Text]